标题
Breast cancer
作者
关键词
-
出版物
LANCET
Volume 397, Issue 10286, Pages 1750-1769
出版商
Elsevier BV
发表日期
2021-04-02
DOI
10.1016/s0140-6736(20)32381-3
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study
- (2021) Erica L Mayer et al. LANCET ONCOLOGY
- Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer—The Penelope-B Trial
- (2021) Sibylle Loibl et al. JOURNAL OF CLINICAL ONCOLOGY
- Nomogram-based estimate of axillary nodal involvement in ACOSOG Z0011 (Alliance): validation and association with radiation protocol variations
- (2020) Matthew S. Katz et al. BREAST CANCER RESEARCH AND TREATMENT
- Cancer statistics, 2020
- (2020) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- BRCA and PALB2 mutations in a cohort of male breast cancer with one bilateral case
- (2020) Maria Teresa Vietri et al. European Journal of Medical Genetics
- Comparison of Abbreviated Breast MRI vs Digital Breast Tomosynthesis for Breast Cancer Detection Among Women With Dense Breasts Undergoing Screening
- (2020) Christopher E. Comstock et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Management of Male Breast Cancer: ASCO Guideline
- (2020) Michael J. Hassett et al. JOURNAL OF CLINICAL ONCOLOGY
- Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update
- (2020) Kimberly H. Allison et al. JOURNAL OF CLINICAL ONCOLOGY
- Antitumor Activity and Safety of Trastuzumab Deruxtecan in Patients With HER2-Low–Expressing Advanced Breast Cancer: Results From a Phase Ib Study
- (2020) Shanu Modi et al. JOURNAL OF CLINICAL ONCOLOGY
- The path to a better biomarker: application of a risk management framework for the implementation of PD‐L1 and TILs as immuno‐oncology biomarkers into breast cancer clinical trials and daily practice
- (2020) Paula I Gonzalez‐Ericsson et al. JOURNAL OF PATHOLOGY
- Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
- (2020) Matthias Guckenberger et al. LANCET ONCOLOGY
- Pembrolizumab for Early Triple-Negative Breast Cancer
- (2020) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Oligometastatic Breast Cancer: Is This a Curable Entity? A Contemporary Review of the Literature
- (2020) Igor Makhlin et al. Current Oncology Reports
- 139O Final results of the double-blind placebo (PBO)-controlled randomised phase II LOTUS trial of first-line ipatasertib (IPAT) + paclitaxel (PAC) for inoperable locally advanced/metastatic triple-negative breast cancer (mTNBC)
- (2020) R. Dent et al. ANNALS OF ONCOLOGY
- The Impact of Primary Tumor Surgery on Survival in HER2 Positive Stage IV Breast Cancer Patients in the Current Era of Targeted Therapy
- (2020) Ross Mudgway et al. ANNALS OF SURGICAL ONCOLOGY
- Do Eligibility Criteria for Ductal Carcinoma In Situ (DCIS) Active Surveillance Trials Identify Patients at Low Risk for Upgrade to Invasive Carcinoma?
- (2020) Tawakalitu O. Oseni et al. ANNALS OF SURGICAL ONCOLOGY
- Overcoming Endocrine Resistance in Breast Cancer
- (2020) Ariella B. Hanker et al. CANCER CELL
- TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2- metastatic breast cancer
- (2020) Hope S Rugo et al. Future Oncology
- Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial
- (2020) Adrian Murray Brunt et al. LANCET
- Radiation therapy to the primary tumor for de novo metastatic breast cancer and overall survival in a retrospective multicenter cohort analysis
- (2020) Elvire Pons-Tostivint et al. RADIOTHERAPY AND ONCOLOGY
- Association of Germline Variant Status With Therapy Response in High-risk Early-Stage Breast Cancer
- (2020) Esther Pohl-Rescigno et al. JAMA Oncology
- Selecting Node-Positive Patients for Axillary Downstaging with Neoadjuvant Chemotherapy
- (2020) Giacomo Montagna et al. ANNALS OF SURGICAL ONCOLOGY
- Spatial location of local recurrences after mastectomy: a systematic review
- (2020) Orit Kaidar-Person et al. BREAST CANCER RESEARCH AND TREATMENT
- Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial
- (2020) Cristina Saura et al. JOURNAL OF CLINICAL ONCOLOGY
- Comparison of conventional and advanced radiotherapy techniques for left-sided breast cancer after breast conserving surgery
- (2020) Yibo Xie et al. Medical Dosimetry
- ESTRO IORT Task Force/ACROP recommendations for intraoperative radiation therapy with electrons (IOERT) in breast cancer
- (2020) Gerd Fastner et al. RADIOTHERAPY AND ONCOLOGY
- Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer
- (2020) Ke-Da Yu et al. JAMA Oncology
- Hypofractionated Versus Standard Fractionated Radiotherapy in Patients With Early Breast Cancer or Ductal Carcinoma In Situ in a Randomized Phase III Trial: The DBCG HYPO Trial
- (2020) Birgitte V. Offersen et al. JOURNAL OF CLINICAL ONCOLOGY
- Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial
- (2020) Icro Meattini et al. JOURNAL OF CLINICAL ONCOLOGY
- Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
- (2020) Stephen R. D. Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial
- (2020) Elizabeth A Mittendorf et al. LANCET
- Changes in Reoperation After Publication of Consensus Guidelines on Margins for Breast-Conserving Surgery
- (2020) M. Luke Marinovich et al. JAMA Surgery
- Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
- (2020) Javier Cortes et al. LANCET
- Breast conservation and axillary management after primary systemic therapy in patients with early-stage breast cancer: the Lucerne toolbox
- (2020) Peter Dubsky et al. LANCET ONCOLOGY
- Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1
- (2020) F. André et al. ANNALS OF ONCOLOGY
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
- (2019) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- A systematic review of international guidelines and recommendations for the genetic screening, diagnosis, genetic counseling, and treatment of BRCA-mutated breast cancer
- (2019) Carol Forbes et al. Cancer Management and Research
- Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
- (2019) Aditya Bardia et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant denosumab in postmenopausal patients with hormone receptor-positive breast cancer (ABCSG-18): disease-free survival results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Michael Gnant et al. LANCET ONCOLOGY
- Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials
- (2019) Richard Gray et al. LANCET
- OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician’s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
- (2019) M E Robson et al. ANNALS OF ONCOLOGY
- Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
- (2019) R Condorelli et al. ANNALS OF ONCOLOGY
- West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer
- (2019) Ulrike Nitz et al. JOURNAL OF CLINICAL ONCOLOGY
- Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2019) Sara M. Tolaney et al. JOURNAL OF CLINICAL ONCOLOGY
- Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia
- (2019) Andrea DeCensi et al. JOURNAL OF CLINICAL ONCOLOGY
- Alpelisib for PIK3CA-Mutated, Hormone Receptor–Positive Advanced Breast Cancer
- (2019) Fabrice André et al. NEW ENGLAND JOURNAL OF MEDICINE
- Post-Mastectomy Radiotherapy After Neoadjuvant Chemotherapy in Breast Cancer: A Pooled Retrospective Analysis of Three Prospective Randomized Trials
- (2019) David Krug et al. ANNALS OF SURGICAL ONCOLOGY
- Breast cancer, placenta and pregnancy
- (2019) Karolin Froehlich et al. EUROPEAN JOURNAL OF CANCER
- 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial
- (2019) Helena M Earl et al. LANCET
- Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer
- (2019) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
- (2019) Seock-Ah Im et al. NEW ENGLAND JOURNAL OF MEDICINE
- A prospective investigation of oral contraceptive use and breast cancer mortality: findings from the Swedish women’s lifestyle and health cohort
- (2019) Ula Nur et al. BMC CANCER
- Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy
- (2019) Francesca Pellini et al. Breast Care
- Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial
- (2019) Hyun-Ah Kim et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update—Integration of Results From TAILORx
- (2019) Fabrice Andre et al. JOURNAL OF CLINICAL ONCOLOGY
- ESTRO ACROP consensus guideline for target volume delineation in the setting of postmastectomy radiation therapy after implant-based immediate reconstruction for early stage breast cancer
- (2019) Orit Kaidar-Person et al. RADIOTHERAPY AND ONCOLOGY
- Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019
- (2019) H J Burstein et al. ANNALS OF ONCOLOGY
- Winter is over: The use of Artificial Intelligence to individualise radiation therapy for breast cancer
- (2019) Philip M.P. Poortmans et al. BREAST
- Breast cancer statistics, 2019
- (2019) Carol E. DeSantis et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- Performance of Dual-Energy Contrast-enhanced Digital Mammography for Screening Women at Increased Risk of Breast Cancer
- (2019) Janice S. Sung et al. RADIOLOGY
- When Can We Avoid Postmastectomy Radiation Following Primary Systemic Therapy?
- (2019) Ángel Montero et al. Current Oncology Reports
- Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial
- (2019) Peter Schmid et al. JOURNAL OF CLINICAL ONCOLOGY
- Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families
- (2019) Xin Yang et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial
- (2019) Jack Cuzick et al. LANCET
- CDK4/6 inhibitor treatment for patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer: a US Food and Drug Administration pooled analysis
- (2019) Jennifer J Gao et al. LANCET ONCOLOGY
- Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer
- (2019) Rashmi K. Murthy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
- (2019) Shanu Modi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
- (2018) F Poggio et al. ANNALS OF ONCOLOGY
- Is Low-Volume Disease in the Sentinel Node After Neoadjuvant Chemotherapy an Indication for Axillary Dissection?
- (2018) Tracy-Ann Moo et al. ANNALS OF SURGICAL ONCOLOGY
- The Feasibility of Breast-Conserving Surgery for Multiple Ipsilateral Breast Cancer: An Initial Report from ACOSOG Z11102 (Alliance) Trial
- (2018) Kari M. Rosenkranz et al. ANNALS OF SURGICAL ONCOLOGY
- Randomized Trial Comparing Resection of Primary Tumor with No Surgery in Stage IV Breast Cancer at Presentation: Protocol MF07-01
- (2018) Atilla Soran et al. ANNALS OF SURGICAL ONCOLOGY
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Gonadotropin-Releasing Hormone Agonists During Chemotherapy for Preservation of Ovarian Function and Fertility in Premenopausal Patients With Early Breast Cancer: A Systematic Review and Meta-Analysis of Individual Patient–Level Data
- (2018) Matteo Lambertini et al. JOURNAL OF CLINICAL ONCOLOGY
- Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update
- (2018) Antonio C. Wolff et al. JOURNAL OF CLINICAL ONCOLOGY
- PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor–Positive Early Breast Cancer
- (2018) Anne-Vibeke Lænkholm et al. JOURNAL OF CLINICAL ONCOLOGY
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials
- (2018) Bernard Asselain et al. LANCET ONCOLOGY
- Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
- (2018) Sibylle Loibl et al. LANCET ONCOLOGY
- Breast Cancer in Men
- (2018) Sharon H. Giordano NEW ENGLAND JOURNAL OF MEDICINE
- Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer
- (2018) Prudence A. Francis et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
- (2018) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Endocrine Therapy in Premenopausal Hormone Receptor Positive/Human Epidermal Growth Receptor 2 Negative Metastatic Breast Cancer: Between Guidelines and Literature
- (2018) Richard Tancredi et al. ONCOLOGIST
- OUP accepted manuscript
- (2018) JNCI-Journal of the National Cancer Institute
- Effect of Adjuvant Trastuzumab for a Duration of 9 Weeks vs 1 Year With Concomitant Chemotherapy for Early Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
- (2018) Heikki Joensuu et al. JAMA Oncology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial
- (2018) Viviana Galimberti et al. LANCET ONCOLOGY
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
- (2018) Jennifer K. Litton et al. NEW ENGLAND JOURNAL OF MEDICINE
- Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response—final results from GeparSixto
- (2018) S Loibl et al. ANNALS OF ONCOLOGY
- Diagnostic Accuracy of Different Surgical Procedures for Axillary Staging After Neoadjuvant Systemic Therapy in Node-positive Breast Cancer
- (2018) Janine M. Simons et al. ANNALS OF SURGERY
- Sentinel lymph node biopsy without axillary lymphadenectomy after neoadjuvant chemotherapy is accurate and safe for selected patients: the GANEA 2 study
- (2018) Jean-Marc Classe et al. BREAST CANCER RESEARCH AND TREATMENT
- Accelerated partial breast irradiation: Current status with a focus on clinical practice
- (2018) Fabiana A. Miranda et al. Breast Journal
- Meta-analysis of sentinel lymph node biopsy after neoadjuvant chemotherapy in patients with initial biopsy-proven node-positive breast cancer
- (2018) S. R. Tee et al. BRITISH JOURNAL OF SURGERY
- Variation in the Use of Boost Irradiation in Breast-Conserving Therapy in the Netherlands: The Effect of a National Guideline and Cofounding Factors
- (2018) K. Schreuder et al. CLINICAL ONCOLOGY
- Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study
- (2018) Marissa C. van Maaren et al. INTERNATIONAL JOURNAL OF CANCER
- Randomized Trial Evaluating Radiation following Surgical Excision for “Good Risk” DCIS: 12-Year Report from NRG/RTOG 9804
- (2018) B. McCormick INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Adjuvant Endocrine Therapy for Women With Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
- (2018) Harold J. Burstein et al. JOURNAL OF CLINICAL ONCOLOGY
- Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor–Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial
- (2018) Thomas Ruhstaller et al. JOURNAL OF CLINICAL ONCOLOGY
- Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2018) Eleftherios P Mamounas et al. LANCET ONCOLOGY
- Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
- (2018) Peter Schmid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer
- (2018) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heart toxicity from breast cancer radiotherapy
- (2018) Marc D. Piroth et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Preoperative breast radiation therapy: Indications and perspectives
- (2017) S.V. Lightowlers et al. EUROPEAN JOURNAL OF CANCER
- Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis
- (2017) Armando E. Giuliano et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers
- (2017) Karoline B. Kuchenbaecker et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Survival benefit of tamoxifen and aromatase inhibitor in male and female breast cancer
- (2017) Holm Eggemann et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Anthracyclines in Early Breast Cancer: The ABC Trials—USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology)
- (2017) Joanne L. Blum et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials
- (2017) Poornima Saha et al. JOURNAL OF CLINICAL ONCOLOGY
- Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
- (2017) Erik J Blok et al. JNCI-Journal of the National Cancer Institute
- Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status
- (2017) Matteo Lambertini et al. JNCI-Journal of the National Cancer Institute
- Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
- (2017) Carsten Denkert et al. LANCET
- Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial
- (2017) Charlotte E Coles et al. LANCET
- Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
- (2017) Nicholas C Turner et al. LANCET
- HER2-positive breast cancer
- (2017) Sibylle Loibl et al. LANCET
- The global burden of women’s cancers: a grand challenge in global health
- (2017) Ophira Ginsburg et al. LANCET
- Radiation oncology enters the era of individualised medicine
- (2017) Philip Poortmans et al. LANCET ONCOLOGY
- Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Miguel Martin et al. LANCET ONCOLOGY
- Late side-effects and cosmetic results of accelerated partial breast irradiation with interstitial brachytherapy versus whole-breast irradiation after breast-conserving surgery for low-risk invasive and in-situ carcinoma of the female breast: 5-year results of a randomised, controlled, phase 3 trial
- (2017) Csaba Polgár et al. LANCET ONCOLOGY
- 20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
- (2017) Hongchao Pan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
- (2017) Mark Robson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
- (2017) Norikazu Masuda et al. NEW ENGLAND JOURNAL OF MEDICINE
- Contemporary Hormonal Contraception and the Risk of Breast Cancer
- (2017) Lina S. Mørch et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer
- (2017) Gunter von Minckwitz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05)
- (2017) Erik J Blok et al. JNCI-Journal of the National Cancer Institute
- Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status
- (2017) Matteo Lambertini et al. JNCI-Journal of the National Cancer Institute
- Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer
- (2017) Eric Hahnen et al. JAMA Oncology
- Trends in Reoperation After Initial Lumpectomy for Breast Cancer
- (2017) Monica Morrow et al. JAMA Oncology
- Supplemental Screening for Breast Cancer in Women With Dense Breasts: A Systematic Review for the U.S. Preventive Services Task Force
- (2016) Joy Melnikow et al. ANNALS OF INTERNAL MEDICINE
- PIK3CAmutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab
- (2016) S. Loibl et al. ANNALS OF ONCOLOGY
- Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II–III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance)
- (2016) Mehra Golshan et al. BREAST CANCER RESEARCH AND TREATMENT
- Male breast cancer in a multi-gene panel testing cohort: insights and unexpected results
- (2016) Mary Pritzlaff et al. BREAST CANCER RESEARCH AND TREATMENT
- Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial
- (2016) Karin Ribi et al. JOURNAL OF CLINICAL ONCOLOGY
- Elective Nodal Irradiation in Breast Cancer: Time for Trials on the Basis of Tumor Biology
- (2016) Lorenzo Livi et al. JOURNAL OF CLINICAL ONCOLOGY
- Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial
- (2016) John F Forbes et al. LANCET
- 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial
- (2016) Luca Gianni et al. LANCET ONCOLOGY
- 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
- (2016) Fatima Cardoso et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Feasibility and Accuracy of Sentinel Lymph Node Biopsy in Initially Clinically Node-Negative Breast Cancer after Neoadjuvant Chemotherapy: A Systematic Review and Meta-Analysis
- (2016) Chong Geng et al. PLoS One
- ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1
- (2016) Birgitte V. Offersen et al. RADIOTHERAPY AND ONCOLOGY
- Neratinib Plus Paclitaxel vs Trastuzumab Plus Paclitaxel in Previously Untreated Metastatic ERBB2-Positive Breast Cancer
- (2016) Ahmad Awada et al. JAMA Oncology
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
- (2015) A. S. Coates et al. ANNALS OF ONCOLOGY
- Impact of Neoadjuvant Chemotherapy in Stage II–III Triple Negative Breast Cancer on Eligibility for Breast-conserving Surgery and Breast Conservation Rates
- (2015) Mehra Golshan et al. ANNALS OF SURGERY
- Breast Cancer Screening for Women at Average Risk
- (2015) Kevin C. Oeffinger et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Relative Effectiveness of Letrozole Compared With Tamoxifen for Patients With Lobular Carcinoma in the BIG 1-98 Trial
- (2015) Otto Metzger Filho et al. JOURNAL OF CLINICAL ONCOLOGY
- Sentinel Node Biopsy After Neoadjuvant Chemotherapy in Biopsy-Proven Node-Positive Breast Cancer: The SN FNAC Study
- (2015) Jean-Francois Boileau et al. JOURNAL OF CLINICAL ONCOLOGY
- Impact of the Addition of Carboplatin and/or Bevacizumab to Neoadjuvant Once-per-Week Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide on Pathologic Complete Response Rates in Stage II to III Triple-Negative Breast Cancer: CALGB 40603 (Alliance)
- (2015) William M. Sikov et al. JOURNAL OF CLINICAL ONCOLOGY
- Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2 × 2 factorial, randomised phase 3 trial
- (2015) Lucia Del Mastro et al. LANCET
- Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials
- (2015) LANCET
- Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial
- (2015) Rajendra Badwe et al. LANCET ONCOLOGY
- Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial
- (2015) Ian H Kunkler et al. LANCET ONCOLOGY
- Prospective Validation of a 21-Gene Expression Assay in Breast Cancer
- (2015) Joseph A. Sparano et al. NEW ENGLAND JOURNAL OF MEDICINE
- Recommendations from GEC ESTRO Breast Cancer Working Group (I): Target definition and target delineation for accelerated or boost Partial Breast Irradiation using multicatheter interstitial brachytherapy after breast conserving closed cavity surgery
- (2015) Vratislav Strnad et al. RADIOTHERAPY AND ONCOLOGY
- Breast Cancer Diagnosed During Pregnancy
- (2015) Sibylle Loibl et al. JAMA Oncology
- Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†
- (2014) M. Piccart et al. ANNALS OF ONCOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Response and prognosis after neoadjuvant chemotherapy in 1,051 patients with infiltrating lobular breast carcinoma
- (2014) Sibylle Loibl et al. BREAST CANCER RESEARCH AND TREATMENT
- Estrogen Receptor Mutations in Breast Cancer--New Focus on an Old Target
- (2014) C. V. Segal et al. CLINICAL CANCER RESEARCH
- Postmastectomy radiation in breast cancer with one to three involved lymph nodes: ending the debate
- (2014) Philip Poortmans LANCET
- Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
- (2014) EBCTCG (Early Breast Cancer Trialists' Collaborative Group) LANCET
- Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
- (2014) Patricia Cortazar et al. LANCET
- Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial
- (2014) Gunter von Minckwitz et al. LANCET ONCOLOGY
- Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial
- (2014) Mila Donker et al. LANCET ONCOLOGY
- Breast-Cancer Risk in Families with Mutations in PALB2
- (2014) Antonis C. Antoniou et al. NEW ENGLAND JOURNAL OF MEDICINE
- Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 Risk of Recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone
- (2013) M. Gnant et al. ANNALS OF ONCOLOGY
- Breast-Conserving Therapy Achieves Locoregional Outcomes Comparable to Mastectomy in Women with T1-2N0 Triple-Negative Breast Cancer
- (2013) Zachary S. Zumsteg et al. ANNALS OF SURGICAL ONCOLOGY
- Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer
- (2013) Judy C. Boughey JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Breast-Conserving Treatment With or Without Radiotherapy in Ductal Carcinoma In Situ: 15-Year Recurrence Rates and Outcome After a Recurrence, From the EORTC 10853 Randomized Phase III Trial
- (2013) Mila Donker et al. JOURNAL OF CLINICAL ONCOLOGY
- Selective oestrogen receptor modulators in prevention of breast cancer: an updated meta-analysis of individual participant data
- (2013) Jack Cuzick et al. LANCET
- The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials
- (2013) Joanne S Haviland et al. LANCET ONCOLOGY
- 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial
- (2013) Xavier Pivot et al. LANCET ONCOLOGY
- Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study
- (2013) Thorsten Kuehn et al. LANCET ONCOLOGY
- Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer
- (2013) Sarah C. Darby et al. NEW ENGLAND JOURNAL OF MEDICINE
- Trastuzumab administration during pregnancy: a systematic review and meta-analysis
- (2012) Flora Zagouri et al. BREAST CANCER RESEARCH AND TREATMENT
- Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients
- (2012) Holm Eggemann et al. BREAST CANCER RESEARCH AND TREATMENT
- Predictors of Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From Combined Analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27
- (2012) Eleftherios P. Mamounas et al. JOURNAL OF CLINICAL ONCOLOGY
- Treatment of breast cancer during pregnancy: an observational study
- (2012) Sibylle Loibl et al. LANCET ONCOLOGY
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
- (2011) Martin Filipits et al. CLINICAL CANCER RESEARCH
- The feasibility and accuracy of sentinel lymph node biopsy in clinically node-negative patients after neoadjuvant chemotherapy for breast cancer-a systematic review and meta-analysis
- (2011) Veronique K.M. Tan et al. JOURNAL OF SURGICAL ONCOLOGY
- Local treatment of metastatic cancer—killing the seed or disturbing the soil?
- (2011) Scott C. Morgan et al. Nature Reviews Clinical Oncology
- Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer
- (2010) V. G. Vogel et al. Cancer Prevention Research
- Multicenter Surveillance of Women at High Genetic Breast Cancer Risk Using Mammography, Ultrasonography, and Contrast-Enhanced Magnetic Resonance Imaging (the High Breast Cancer Risk Italian 1 Study)
- (2010) Francesco Sardanelli et al. INVESTIGATIVE RADIOLOGY
- Prospective Multicenter Cohort Study to Refine Management Recommendations for Women at Elevated Familial Risk of Breast Cancer: The EVA Trial
- (2010) Christiane Kuhl et al. JOURNAL OF CLINICAL ONCOLOGY
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer
- (2010) M. Elizabeth H. Hammond et al. JOURNAL OF CLINICAL ONCOLOGY
- Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer
- (2010) Timothy J. Whelan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: Recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009)
- (2010) Csaba Polgár et al. RADIOTHERAPY AND ONCOLOGY
- Impact of breast surgery on survival in patients with distant metastases at initial presentation: a systematic review of the literature
- (2009) Jetske Ruiterkamp et al. BREAST CANCER RESEARCH AND TREATMENT
- Local relapse rates are falling after breast conserving surgery and systemic therapy for early breast cancer: Can radiotherapy ever be safely withheld?
- (2008) Mariella Mannino et al. RADIOTHERAPY AND ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started